TCR-like CAR-T
Phase 2Cell therapy
TCR-like CAR-T is one of 49 biologic programs targeting Ovarian Cancer. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
48
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
207 competitors in Ovarian Cancer
#DrugCompanyPhaseTrials
1Hycamtin
MMeitheal
Phase 3
Pegylated Liposomal Doxorubicin
Merck & Co.Phase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Opdivo
Bristol-Myers SquibbPhase 3
Lynparza
RRisen (Suzhou) Pharma Tech Co., Ltd.
Phase 3
Afinitor
NovartisPhase 3
Neulasta
AmgenPhase 3
Taxotere
AAvyxa
Phase 3
Elahere
IImmunogenics, LLC
Phase 3
Sporanox
SSebela Pharmaceuticals Development LLC
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TCR-like CAR-T. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Phase 2[1]
- Company
- ZZhongda Hospital